Use of VELCADE® as a single agent in patients with 1 to 3 prior therapies was established in APEX: a prospective, comparative, randomized, stratified, open-label clinical trial in patients with progressive
multiple myeloma (N = 669).
Study Parameters
Primary endpoint: time to progression; secondary endpoints: survival, overall response rate, duration of response, safety
Exclusion criteria included: patients refractory to high-dose dexamethasone and patients with a platelet count less than 50,000/μL or with baseline greater than or equal to grade 2 peripheral neuropathy
8-Cycle Induction Phase Followed by Maintenance Treatment
Please click here to view additional important safety information.
For full Prescribing Information click here. (pdf) (74KB)
For further information about VELCADE® (bortezomib) for Injection, call 1-866-VELCADE (U.S. clinicians only).
